Goldman Sachs’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.72M | Sell |
1,131,218
-364,645
| -24% | -$1.85M | ﹤0.01% | 2700 |
|
|
2025
Q1 | $7.91M | Sell |
1,495,863
-569,345
| -28% | -$3.01M | ﹤0.01% | 2398 |
|
|
2024
Q4 | $14M | Buy |
2,065,208
+525,504
| +34% | +$3.55M | ﹤0.01% | 2071 |
|
|
2024
Q3 | $10.1M | Buy |
1,539,704
+469,154
| +44% | +$3.09M | ﹤0.01% | 2248 |
|
|
2024
Q2 | $8.03M | Buy |
1,070,550
+173,530
| +19% | +$1.3M | ﹤0.01% | 2268 |
|
|
2024
Q1 | $8.94M | Sell |
897,020
-294,785
| -25% | -$2.94M | ﹤0.01% | 2140 |
|
|
2023
Q4 | $11.8M | Buy |
1,191,805
+527,032
| +79% | +$5.2M | ﹤0.01% | 1951 |
|
|
2023
Q3 | $5.09M | Buy |
664,773
+87,328
| +15% | +$668K | ﹤0.01% | 2452 |
|
|
2023
Q2 | $4.31M | Buy |
577,445
+42,318
| +8% | +$316K | ﹤0.01% | 2671 |
|
|
2023
Q1 | $3.57M | Sell |
535,127
-47,875
| -8% | -$319K | ﹤0.01% | 2797 |
|
|
2022
Q4 | $4.49M | Buy |
583,002
+224,936
| +63% | +$1.73M | ﹤0.01% | 2707 |
|
|
2022
Q3 | $3.81M | Buy |
358,066
+161,999
| +83% | +$1.72M | ﹤0.01% | 2860 |
|
|
2022
Q2 | $1.6M | Sell |
196,067
-13,342
| -6% | -$109K | ﹤0.01% | 3613 |
|
|
2022
Q1 | $1.5M | Buy |
209,409
+85,823
| +69% | +$614K | ﹤0.01% | 3795 |
|
|
2021
Q4 | $2.12M | Buy |
123,586
+104,919
| +562% | +$1.8M | ﹤0.01% | 3457 |
|
|
2021
Q3 | $429K | Buy |
18,667
+7,654
| +69% | +$176K | ﹤0.01% | 4469 |
|
|
2021
Q2 | $402K | Buy |
+11,013
| New | +$402K | ﹤0.01% | 4543 |
|